Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis

Reactivation of herpesvirus under fingolimod: A case of severe herpes simplex encephalitis

(2015) N. Pfender et al.   NEUROLOGY

Varicella-Zoster Virus Infections in Patients Treated With Fingolimod

(2015) Ann M. Arvin et al.   JAMA Neurology

Cardiac and vascular effects of fingolimod: Mechanistic basis and clinical implications

(2014) John Camm et al.   AMERICAN HEART JOURNAL

Second-Line Therapy with Fingolimod for Relapsing-Remitting Multiple Sclerosis in Clinical Practice: The Effect of Previous Exposure to Natalizumab

(2014) Assunta Bianco et al.   EUROPEAN NEUROLOGY

Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial

(2014) T. Olsson et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Population pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator

(2014) Andreas Krause et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

(2014) Peter A Calabresi et al.   LANCET NEUROLOGY

Relapses in patients treated with fingolimod after previous exposure to natalizumab

(2014) G Comi et al.   Multiple Sclerosis Journal

ACTRIMS-ECTRIMS MSBoston 2014: Late Breaking News Oral Presentations

(2014)   Multiple Sclerosis Journal

Fingolimod after natalizumab and the risk of short-term relapse

(2014) V. G. Jokubaitis et al.   NEUROLOGY

Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis

(2014) G. Karlsson et al.   NEUROLOGY

Switching From Natalizumab to Fingolimod in Multiple Sclerosis

(2014) Mikael Cohen et al.   JAMA Neurology

Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study

(2013) Krzysztof Selmaj et al.   LANCET NEUROLOGY

Ophthalmic Evaluations in Clinical Studies of Fingolimod (FTY720) in Multiple Sclerosis

(2013) Marco A. Zarbin et al.   OPHTHALMOLOGY

The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate

(2012) P Gergely et al.   BRITISH JOURNAL OF PHARMACOLOGY

Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis

(2011) Jeffrey A. Cohen et al.   ANNALS OF NEUROLOGY

Natalizumab and drug holiday in clinical practice: An observational study in very active relapsing remitting Multiple Sclerosis patients

(2011) A. Kerbrat et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis

(2011) M. Mehling et al.   NEUROLOGY

Immune Reconstitution Inflammatory Syndrome in Patients With Multiple Sclerosis Following Cessation of Natalizumab Therapy

(2010) Augusto Miravalle et al.   ARCHIVES OF NEUROLOGY

Mechanism of Action of Oral Fingolimod (FTY720) in Multiple Sclerosis

(2010) Jerold Chun et al.   CLINICAL NEUROPHARMACOLOGY

A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis

(2010) Ludwig Kappos et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis

(2010) Jeffrey A. Cohen et al.   NEW ENGLAND JOURNAL OF MEDICINE